by Jason M. Brocks , Legal Analyst, Bloomberg Law Pharmaceutical companies may begin to rethink their pipeline and marketing strategies in light of the U.S. District Court’s highly technical analysis of the language of the Medicare law. The court’s opinion resulted in a denial of reimbursement to a Medicare Part D beneficiary for a drug [...]
Proponents of global coordination on benchmark rate-setting rules say varying proposals on their composition, governance and supervision may convince some companies to do business in less-regulated countries. Click here to continue reading.
ETFs focused on Italy reported last week the largest outflows since the beginning of 2012, right before the parliamentary elections on Feb. 24-25
This podcast was recorded at 2pm EST on Feb 21. Click here to listen
Libor-tied note sales surge in February in the U.S. on the strength of a $250 million offering from Morgan Stanley. Check out our front page this week.
by Michael Manns, Senior Equity Analyst & Jason McGorman, Equity Analyst, Bloomberg Industries China is now the world‘s second largest market for medical equipment, behind the U.S. Hospitals have purchased imaging and diagnostic equipment in compliance with the 2009 health reform that included a $124 billion stimulus package to build medical clinics in every village [...]
The cost to implement provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act more than tripled at four regulators in 2012 from 2011, the U.S. Government Accountability Office said in a report. Click here to continue reading.
Here’s our page 1 this week for Structured Notes — Morgan Stanley is the No. 1 issuer in the U.S. for the first time since August 2011, Incapital sues employees they say resigned after stealing proprietary secrets, and Swapnil Pawar talks about why he’s bullish on the India market.
Air Lease expects to issue $500 million to $1 billion of new debt annually to help pay for the almost $1.5 billion a year in aircraft acquisition commitments it has scheduled. It will mainly target unsecured fixed-rate debt. Click here to read more
Pfizer’s novel rheumatoid arthritis drug (RA) Xeljanz has had a strong launch in the U.S. Initial analysis of prescription data from Symphony Health Solutions suggests that Xeljanz use will not be limited to patients who have an inadequate response to TNF inhibitors, which currently dominate the market. Additional data on a higher dose and use [...]